Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSB | P07858 | 1/20 | 0.54 |
| ▸ | CTSS | P25774 | 1/20 | 0.54 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.39 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.32 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 1/20 | 0.32 |
| ▸ | GABRA3 | P34903 | 1/20 | 0.32 |
| ▸ | GABRA2 | P47869 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8247343 | 1.00 | CTSB (0.54) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383647 | 1.00 | CTSB (0.54) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383645 | 1.00 | CTSB (0.54) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL8245335 | 0.93 | CTSS (0.53) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2382705 | 0.91 | CTSS (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2382700 | 0.91 | CTSS (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2382696 | 0.91 | CTSS (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL12253398 | 0.91 | CTSS (0.63) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383129 | 0.91 | CTSS (0.67) | CTSBCTSSADRB3ADRA2BADRA2C | |
| SCHEMBL2383127 | 0.91 | CTSS (0.67) | CTSBCTSSADRB3ADRA2BADRA2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1919904-B1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN R & D IRELAND (IE) | 2014-01-08 | — | — | EP | disclosed |
| US-8012939-B2 | Macrocyclic inhibitors of hepatitis C virus | Tibotec Pharmaceuticals Ltd. Co (IE) | 2011-09-06 | — | — | US | disclosed |
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | JANSSEN SCIENCES IRELAND UC (IE) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090281141-A1 | MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS | CBR1, HCCS, CYP2B6 | CTSB 3926/4885CTSS 3118/4885ADRB3 2695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.